Figures & data
Table 1 Unit costs in Euros at 2012/2013 prices
Figure 1 Expected probability of infants developing tolerance to cow’s milk by 18 months after starting a formula.
![Figure 1 Expected probability of infants developing tolerance to cow’s milk by 18 months after starting a formula.](/cms/asset/5e6dc41f-374d-492e-bf77-2408f703d07e/dceo_a_89347_f0001_c.jpg)
Table 2 Expected levels of health care resource use and corresponding costs in Euros at 2012/2013 prices over 18 months from starting a formula
Table 3 Cost-effectiveness of eHCF + LGG versus eHCF and eHCF versus AAF
Figure 2 (A) Distribution of expected SNS costs over 18 months from starting a formula and expected probability of developing tolerance to cow’s milk by 18 months among IgE-mediated allergic infants, generated by 10,000 iterations of the model. (B) Distribution of expected SNS costs over 18 months from starting a formula and expected probability of developing tolerance to cow’s milk by 18 months among non–IgE-mediated allergic infants, generated by 10,000 iterations of the model.
![Figure 2 (A) Distribution of expected SNS costs over 18 months from starting a formula and expected probability of developing tolerance to cow’s milk by 18 months among IgE-mediated allergic infants, generated by 10,000 iterations of the model. (B) Distribution of expected SNS costs over 18 months from starting a formula and expected probability of developing tolerance to cow’s milk by 18 months among non–IgE-mediated allergic infants, generated by 10,000 iterations of the model.](/cms/asset/9604e534-545e-4c5b-89c6-1cb54ceb88b9/dceo_a_89347_f0002_c.jpg)
Figure 3 (A) Probability of being cost-effective at different cost-effectiveness thresholds for IgE-mediated allergic infants, from the perspective of the SNS. (B) Probability of being cost-effective at different cost-effectiveness thresholds for non–IgE-mediated allergic infants, from the perspective of the SNS.
![Figure 3 (A) Probability of being cost-effective at different cost-effectiveness thresholds for IgE-mediated allergic infants, from the perspective of the SNS. (B) Probability of being cost-effective at different cost-effectiveness thresholds for non–IgE-mediated allergic infants, from the perspective of the SNS.](/cms/asset/e913e073-18f1-4e92-b5ac-004fa97edd33/dceo_a_89347_f0003_c.jpg)
Table 4 Deterministic sensitivity analyses